Current treatment and management of dystrophinopathies

Current Treatment Options in Neurology

Volumn 16, Issue 5, 2014, Pages

  Goemans, Nathalie ^a   Buyse, Gunnar ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Cardiac management; Duchenne; Dystrophinopathies; Glucocorticosteroids; Management; Muscle degeneration; Muscular dystrophy; Respiratory management; Therapy; Treatment

Indexed keywords

25 HYDROXYVITAMIN D; ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DEFLAZACORT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DYSTROPHIN; GLUCOSE; METFORMIN; PREDNISONE;

ACHILLES TENDON; APPETITE; BLADDER DYSFUNCTION; BODY FAT; BODY WEIGHT DISORDER; BONE DEMINERALIZATION; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE MINERALIZATION; BONE TURNOVER; BREATHING MUSCLE; CALCIUM METABOLISM; CALORIC INTAKE; CARDIOPULMONARY FUNCTION; CATARACT; CHEMICAL STRUCTURE; CLINICAL PRACTICE; COMORBIDITY; CONCENTRIC MUSCLE CONTRACTION; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONSTIPATION; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; COUGHING; CUSHINGOID SYNDROME; DAILY LIFE ACTIVITY; DARK ADAPTATION; DEATH; DELAYED PUBERTY; DIAPHRAGM; DISORDERS OF CARBOHYDRATE METABOLISM; DUCHENNE MUSCULAR DYSTROPHY; ECCENTRIC MUSCLE CONTRACTION; ENDURANCE TRAINING; EXERCISE; FLUID RETENTION; FOLLOW UP; FOOT ORTHOSIS; GASTROESOPHAGEAL REFLUX; GLOMERULUS FILTRATION RATE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GROWTH INHIBITION; GROWTH RATE; HEALTH CARE QUALITY; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART MUSCLE; HEART MUSCLE INJURY; HEREDITY; HUMAN; HYPERTENSION; HYPOCALCIURIA; HYPOVENTILATION; IMMOBILIZATION; INCIDENCE; INSULIN RESISTANCE; ION TRANSPORT; KIDNEY; KIDNEY FUNCTION; LEG FRACTURE; LIFE EXPECTANCY; LIFE SATISFACTION; LIPID METABOLISM; LIPID STORAGE; LONGEVITY; MEMBRANE DAMAGE; MOBILIZATION; MORBIDITY; MOTOR PERFORMANCE; MULTICENTER STUDY (TOPIC); MUSCLE ATROPHY; MUSCLE CONTRACTURE; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYCOSIS; MYOGLOBINURIA; NONINVASIVE VENTILATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITION; NUTRITIONAL STATUS; OBESITY; ORTHOPEDIC SURGEON; ORTHOTICS; OSMOTIC PRESSURE; OSTEOPOROSIS; PATHOGENESIS; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PHOTOPIC VISION; PHYSICAL ACTIVITY; PHYSICAL DISEASE; PHYSICAL INACTIVITY; PHYSIOTHERAPIST; PROGNOSIS; PROPHYLAXIS; PROSPECTIVE STUDY; PROTEIN SYNTHESIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REM SLEEP; RESISTANCE TRAINING; RESPIRATORY CARE; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SCOLIOSIS; SKELETAL MUSCLE; SPINE FRACTURE; SPINE MALFORMATION; STOMACH EMPTYING; SURGICAL RISK; SURVIVAL; SWALLOWING; TENDON CONTRACTURE; TISSUE DOPPLER IMAGING; TRACHEOSTOMY; TREATMENT DURATION; TUBERCULOSIS; URINE LEVEL; WEIGHT GAIN;

EID: 84895665960     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-014-0287-4     Document Type: Review

References (79)

1. Emery AE. Population frequencies of inherited neuromuscular diseases - a world survey. Neuromuscul Disord. 1991;1:19-29.
2. Mendell JR, Shilling C, Leslie ND, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol. 2012;71:304-13.
3. Hoffman EP, Brown Jr RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919-28.
4. Brooke MH, Fenichel GM, Griggs RC, et al. Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology. 1989;39:475-81. (Pubitemid 19105758)
5. Rideau Y, Jankowski LW, Grellet J. Respiratory function in the muscular dystrophies. Muscle Nerve. 1981;4:155-64. (Pubitemid 11134197)
6. Muntoni F. Cardiomyopathy in muscular dystrophies. Curr Opin Neurol. 2003;16:577-83. (Pubitemid 37290087)
7. Moxley III RT, Pandya S, Ciafaloni E, et al. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol. 2010;25:1116-29.
8. Eagle M, Baudouin SV, Chandler C, et al. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord. 2002;12:926-9. (Pubitemid 35408673)
9. Eagle M, Bourke J, Bullock R, et al. Managing Duchenne muscular dystrophy-the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord. 2007;17:470-5. (Pubitemid 46795560)
10. • Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77-93. This paper is a consensus statement on diagnosis and management of Duchenne muscular dystrophy based on litterature review and scientists opinion.
11. • Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010;9:177-89. This paper is the second part of a consensus statement on diagnosis and management of Duchenne muscular dystrophy based on litterature review and scientists opinion.
12. Fisher I, Abraham D, Bouri K, et al. Prednisolone-induced changes in dystrophic skeletal muscle. FASEB J. 2005;19:834-6. (Pubitemid 40617400)
13. Mendell JR, Moxley RT, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med. 1989;320:1592-7. (Pubitemid 19154573)
14. Henricson EK, Abresch RT, Cnaan A, et al. The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle Nerve. 2013;48:55-67.
15. Biggar WD, Politano L, Harris VA, et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscul Disord. 2004;14:476-82. (Pubitemid 39141702)
16. Biggar WD, Gingras M, Fehlings DL, et al. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr. 2001;138:45-50. (Pubitemid 32097140)
17. Biggar WD, Harris VA, Eliasoph L, et al. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord. 2006;16:249-55.
18. Dec GW. Steroid therapy effectively delays Duchenne's cardiomyopathy. J Am Coll Cardiol. 2013;61:955-6.
19. Markham LW, Kinnett K, Wong BL, et al. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord. 2008;18:365-70.
20. King WM, Ruttencutter R, Nagaraja HN, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology. 2007;68:1607-13. (Pubitemid 46717986)
21. Lebel DE, Corston JA, McAdam LC, et al. Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: long-term follow-up. J Bone Joint Surg (Am Vol). 2013;95:1057-61.
22. Manzur AY, Kuntzer T, Pike M, et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2004;(2):CD003725.
23. Manzur AY, Kuntzer T, Pike M, et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008;(1):CD003725.
24. Mesa LE, Dubrovsky AL, Corderi J, et al. Steroids in Duchenne muscular dystrophy-deflazacort trial. Neuromuscul Disord. 1991;1:261-6.
25. Griggs RC, Herr BE, Reha A, et al. Corticosteroids in Duchenne muscular dystrophy: Major variations in practice. Muscle Nerve. 2013;48:27-31.
26. Griggs RC, Moxley RT, Mendell JR, et al. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol. 1991;48:383-8.
27. Straathof CS, Overweg-Plandsoen WC, van den Burg GJ, et al. Prednisone 10 days on/10 days off in patients with Duchenne muscular dystrophy. J Neurol. 2009;256:768-73.
28. Ricotti V, Ridout DA, Scott E, et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry. 2013;84:698-705.
29. Escolar DM, Hache LP, Clemens PR, et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology. 2011;77:444-52.
30. Kieny P, Chollet S, Delalande P, et al. Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011. Ann Phys Rehabil Med. 2013;56:443-54.
31. PassamanoL, TagliaA, PalladinoA, et al. Improvementof survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients. Acta Myol. 2012;31:121-5.
32. Finder JD, Birnkrant D, Carl J, et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med. 2004;170:456-65. (Pubitemid 39214623)
33. Dohna-Schwake C, Ragette R, Teschler H, et al. IPPB-assisted coughing in neuromuscular disorders. Pediatr Pulmonol. 2006;41:551-7. (Pubitemid 43801025)
34. Miske LJ, Hickey EM, Kolb SM, et al. Use of the mechanical in-exsufflator in pediatric patients with neuromuscular disease and impaired cough. Chest. 2004;125:1406-12. (Pubitemid 38501357)
35. Bach JR, Campagnolo DI, Hoeman S. Life satisfaction of individuals with Duchenne muscular dystrophy using long-term mechanical ventilatory support. Am J Phys Med Rehabil. 1991;70:129-35.
36. Kohler M, Clarenbach CF, Boni L, et al. Quality of life, physical disability, and respiratory impairment in Duchenne muscular dystrophy. Am J Respir Crit Care Med. 2005;172:1032- 6.
37. Rahbek J, Werge B, Madsen A, et al. Adult life with Duchenne muscular dystrophy: observations among an emerging and unforeseen patient population. Pediatr Rehabil. 2005;8:17-28. (Pubitemid 40127948)
38. • Allen HD, Thrush PT, Hoffman TM, et al. Cardiac management in neuromuscular diseases. Phys Med Rehabil Clin North Am. 2012;23:855-68. This paper gives a good review on cardiac aspects of neuromuscular disorders.
39. Bushby K, Muntoni F, Bourke JP. 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. June 7-9, 2002, Naarden, The Netherlands. Neuromuscul Disord. 2003;13:166-72. (Pubitemid 36140013)
40. American Academy of Pediatrics Section on C, Cardiac S. Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy. Pediatrics. 2005;116:1569-73.
41. Mertens L, Ganame J, Claus P, et al. Early regional myocardial dysfunction in young patients with Duchenne muscular dystrophy. J Am Soc Echocardiogr. 2008;21:1049-54.
42. Ryoke T, Gu Y, Mao L, et al. Progressive cardiac dysfunction and fibrosis in the cardiomyopathic hamster and effects of growth hormone and angiotensin-converting enzyme inhibition. Circulation. 1999;100:1734-43. (Pubitemid 29485257)
43. Spurney CF, Sali A, Guerron AD, et al. Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. J Cardiovasc Pharmacol Therapeut. 2011;16:87-95.
44. Duboc D, Meune C, Lerebours G, et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol. 2005;45:855-7. (Pubitemid 40342808)
45. Jefferies JL, Eidem BW, Belmont JW, et al. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation. 2005;112:2799-804. (Pubitemid 41641674)
46. • Politano L, Nigro G. Treatment of dystrophinopathic cardiomyopathy: review of the literature and personal results. Acta Myol. 2012;31:24-30. This paper gives a good review on cardiac aspects of neuromuscular disorders.
47. Spurney CF. Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions. Muscle Nerve. 2011;44:8-19.
48. Dubowitz V. Prevention of deformities. Isr J Med Sci. 1977;13:183-8. (Pubitemid 8090526)
49. McDonald CM. Limb contractures in progressive neuromuscular disease and the role of stretching, orthotics, and surgery. Phys Med Rehabil Clin North Am. 1998;9:187-211. (Pubitemid 28134027)
50. McDonald CM, Abresch RT, Carter GT, et al. Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehabil. 1995;74:S70-92.
51. Scott OM, Hyde SA, Goddard C, et al. Prevention of deformity in Duchenne muscular dystrophy. A prospective study of passive stretching and splintage. Physiotherapy. 1981;67:177-80. (Pubitemid 11032993)
52. Bakker JP, de Groot IJ, Beckerman H, et al. The effects of knee-ankle-foot orthoses in the treatment of Duchenne muscular dystrophy: review of the literature. Clin Rehabil. 2000;14:343-59. (Pubitemid 30495202)
53. Forst J, Forst R. Lower limb surgery in Duchenne muscular dystrophy. Neuromuscul Disord. 1999;9:176-81. (Pubitemid 29336033)
54. Alman BA, Raza SN, Biggar WD. Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy. J Bone Joint Surg (Am Vol). 2004;86-A:519-24. (Pubitemid 38269022)
55. Yilmaz O, Karaduman A, Topaloglu H. Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. Eur J Neurol. 2004;11:541-4. (Pubitemid 39062093)
56. Smith AD, Koreska J, Moseley CF. Progression of scoliosis in Duchenne muscular dystrophy. J Bone Joint Surg (Am Vol). 1989;71:1066-74.
57. Bianchi ML, Biggar D, Bushby K, et al. Endocrine aspects of Duchenne muscular dystrophy. Neuromuscul Disord. 2011;21:298-303.
58. Leung DG, Germain-Lee EL, Denger BE, et al. Report on the Second Endocrine Aspects Of Duchenne Muscular Dystrophy Conference December 1-2, 2010, Baltimore, Maryland, USA. Neuromuscul Disord. 2011;21:594-601.
59. Bianchi ML, Mazzanti A, Galbiati E, et al. Bone mineral density and bone metabolism in Duchenne muscular dystrophy. Osteoporos Int. 2003;14:761-7. (Pubitemid 37295839)
60. Bothwell JE, Gordon KE, Dooley JM, et al. Vertebral fractures in boys with Duchenne muscular dystrophy. Clin Pediatr. 2003;42:353-6. (Pubitemid 36909149)
61. Larson CM, Henderson RC. Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthoped. 2000;20:71-4. (Pubitemid 30013402)
62. Nagel BH, Mortier W, Elmlinger M, et al. Short stature in Duchenne muscular dystrophy: a study of 34 patients. Acta Paediatr. 1999;88:62-5. (Pubitemid 29100202)
63. Rutter MM, Collins J, Rose SR, et al. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure. Neuromuscul Disord. 2012;22:1046-56.
64. Bertelloni S, Baroncelli GI, Garofalo P, et al. Androgen therapy in hypogonadal adolescent males. Horm Res Paediatr. 2010;74:292-6.
65. Casteels K, Fieuws S, van Helvoirt M, et al. Metformin therapy to reduce weight gain and visceral adiposity in children and adolescents with neurogenic or myogenic motor deficit. Pediatr Diabetes. 2010;11:61-9.
66. Hoffman EP, Hudecki MS, Rosenberg PA, et al. Cell and fiber-type distribution of dystrophin. Neuron. 1988;1:411-20.
67. Jaffe KM, McDonald CM, Ingman E, et al. Symptoms of upper gastrointestinal dysfunction in Duchenne muscular dystrophy: case-control study. Arch Phys Med Rehabil. 1990;71:742-4. (Pubitemid 20283084)
68. Haenggi T, Fritschy JM. Role of dystrophin and utrophin for assembly and function of the dystrophin glycoprotein complex in non-muscle tissue. Cell Mol Life Sci. 2006;63:1614-31. (Pubitemid 44252175)
69. Haenggi T, Schaub MC, Fritschy JM. Molecular heterogeneity of the dystrophin-associated protein complex in the mouse kidney nephron: differential alterations in the absence of utrophin and dystrophin. Cell Tissue Res. 2005;319:299-313. (Pubitemid 40174523)
70. Matsumura T, Saito T, Fujimura H, et al. Renal dysfunction is a frequent complication in patients with advanced stage of Duchenne muscular dystrophy. Rinsho Shinkeigaku = Clin Neurol. 2012;52:211-7.
71. Matsumura T, Saito T, Fujimura H, Shinno S, Sakoda S. A longitudinal cause-of-death analysis of patients with Duchenne muscular dystrophy. Rinsho Shinkeigaku = Clin Neurol. 2011;51:743-50.
72. Costa MF, Oliveira AG, Feitosa-Santana C, Zatz M, Ventura DF. Red-green color vision impairment in Duchenne muscular dystrophy. Am J Hum Genet. 2007;80:1064-75. (Pubitemid 47579343)
73. Pascual Pascual SI, Molano J, Pascual-Castroviejo I. Electroretinogram in Duchenne/Becker muscular dystrophy. Pediatr Neurol. 1998;18:315-20. (Pubitemid 28191524)
74. Pillers DA, Fitzgerald KM, Duncan NM, et al. Duchenne/Becker muscular dystrophy: correlation of phenotype by electroretinography with sites of dystrophin mutations. Hum Genet. 1999;105:2 - 9.
75. Topin N, Matecki S, Le Bris S, et al. Dose-dependent effect of individualized respiratory muscle training in children with Duchenne muscular dystrophy. Neuromuscul Disord. 2002;12:576- 83.
76. Sveen ML, Jeppesen TD, Hauerslev S, et al. Endurance training improves fitness and strength in patients with Becker muscular dystrophy. Brain. 2008;131:2824-31.
77. Jansen M, van Alfen N, Geurts AC, et al. Assisted bicycle training delays functional deterioration in boys with duchenne muscular dystrophy: the randomized controlled trial "no use is disuse". Neurorehabil Neural Repair. 2013;27:816-27.
78. • Anziska Y, Sternberg A. Exercise in neuromuscular disease. Muscle Nerve. 2013;48:3-20. This paper reports the latest published evidences and highlights the areas of controversies in relation to exercise modalities in neuromuscular disorders.
79. Markert CD, Case LE, Carter GT, et al. Exercise and Duchenne muscular dystrophy: where we have been and where we need to go. Muscle Nerve. 2012;45:746-51.